Frasers Group: The Berkshire Hathaway of British retail

(Full access for Members only)

Frasers Group: The Berkshire Hathaway of British retail

14 March 2024

Even among London-listed mid-caps with GBP 4bn (USD 5bn) market cap, you can find overlooked, underanalysed opportunities.

The stock of leading British retailer Frasers Group should have investors chomping at the bits to buy a stake:

  • Duopolistic market share in its core business, sports goods.
  • Strong, profitable growth in its new premium and luxury division.
  • Excellent track record for opportunistic investments in companies and real estate.

However, a few factors have long stood in the company's way:

  • A founder and major shareholder that the media portrayed as oaf.
  • A new expansion strategy that was doubted by many.
  • No effort made to woo the financial industry.

This situation is about to change.

This research report explains what to expect in great detail – possibly in greater detail than any other research report has done before.

It will put you ahead of the crowd, and point you towards a stock that might be one of the best asymmetric opportunities you can currently find on the London market.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.